

About Genmab


Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab's vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people's lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

At-a-glance


Our Strengths and Differentiators

- **World-class antibody biology knowledge** and deep insight into disease targets
- **Discovery and development engine** with proprietary technologies that allow us to build a world-class pipeline
- **In-house expertise** with solid track record of building successful strategic partnerships
- **Robust pipeline** of potential best-in-class and first-in-class therapies
- **Experienced, diverse management team**

How we Operate



Genmab's Growing Organization & Growing Presence



Operational

5 Approved Medicines Including Genmab's Innovation

TIVDAK™ in partnership with Seagen, first Genmab owned product on market

DARZALEX® and RYBREVAANT® developed & marketed by Janssen

Kesimpta® developed & marketed by Novartis

TEPEZZA® developed & marketed by Horizon Therapeutics

4 Proprietary Technologies

DuoBody® platform, HexaBody® platform, DuoHexaBody® platform & HexElect® platform

6 Proprietary* Antibody Products in Clinical Development

Tisotumab vedotin, epcoritamab, DuoBody-PD-L1x4-1BB (GEN1046), DuoBody-CD40x4-1BB (GEN1042), DuoHexaBody-CD37 (GEN3009), HexaBody-CD38 (GEN3014)

39 Cumulative INDs since 1999


Created by Genmab or with Genmab's technologies

*Tisotumab vedotin 50:50 partnership with Seagen; epcoritamab, DuoHexaBody-CD37 and DuoBody-CD3x5T4 50:50 partnership with AbbVie; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB 50:50 partnership with BioNTech; HexaBody-CD38, exclusive worldwide license and option agreement with Janssen Biotech, Inc.

Financial

DKK 161B 2020 year-end market cap	DKK 16,079M 2020 year-end cash position
DKK 10,111M 2020 revenue 88% increase versus 2019	DKK 3,798M 2020 operating expenses 83% invested in R&D

Operating Result



Our Purpose

To improve the lives of patients with cancer by creating and developing innovative and differentiated antibody products

Our Vision

By 2025, our own product has transformed cancer treatment, and we have a pipeline of knock-your-socks-off antibodies

Our Values

- Passion for innovation
- Determined – being the best at what we do
- Integrity – we do the right thing
- We work as one team & respect each other

Our Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable and successful biotech

Strong Pipeline of 1st-in-class / Best-in-class Product Candidates



Genmab Proprietary¹ Products

Product	Target	Developed by	Indications	Most Advanced Dev. Phase					Appr.
				Pre-clin.	I	I/II	II	III	
Tisotumab vedotin	TF	Co-developed Genmab/Seagen Inc.	Cervical cancer ² Ovarian cancer Solid tumors						✓
Epcoritamab	CD3, CD20	Co-developed Genmab/AbbVie Inc.	R/R DLBCL B-cell NHL B-cell NHL (combo) R/R CLL						
DuoBody-PD-L1x4-1BB	PD-L1, 4-1BB	Co-developed Genmab/ BioNTech	Solid tumors						
DuoBody-CD40x4-1BB	CD40, 4-1BB	Co-developed Genmab/ BioNTech	Solid tumors						
DuoHexaBody-CD37	CD37	Co-developed Genmab/AbbVie Inc.	Hem. malig.						
HexaBody-CD38	CD38	Genmab ³	Hem. malig.						

Products Incorporating Genmab's Innovation⁴

Approved Medicines

Product	Technology	Developed by	Indication(s)	Most Advanced Dev. Phase					
Daratumumab	UltiMAb®	Janssen	MM ² AL Amyloidosis ² Non-MM blood cancers						✓ ✓
Ofatumumab	UltiMAb	Novartis	RMS ²						✓
Teprotumumab	UltiMAb	Horizon	Thyroid eye disease ²						✓
Amivantamab	DuoBody	Janssen	NSCLC ² Advanced or metastatic gastric or esophageal cancer						✓

≥Phase 2 Clinical-stage Programs

Inclacumab	UltiMAb	Global blood therapeutics	VOC in sickle cell disease						
Teclistamab	DuoBody	Janssen	R/R MM						
Talquetamab	DuoBody	Janssen	R/R MM						
Camidanlumab tesirine	UltiMAb	ADC	R/R Hodgkin lymphoma						
PRV-015 (AMG 714)	UltiMAb	Provention Bio	Celiac disease						
Mim8	DuoBody	Novo Nordisk	Hemophilia A						

Proprietary Technologies Allow us to Build a World-class Pipeline

DuoBody Platform

- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

HexaBody Platform

- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

DuoHexaBody Platform

- Antibody technology that combines DuoBody & HexaBody platforms
- Creates bispecific antibodies with target mediated enhanced potency

HexElect Platform

- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting with enhanced selectivity & potency

Executive Management:

Jan G. J. van de Winkel, Ph.D. President & CEO
 Anthony Pagano, EVP & CFO
 Judith Klimovsky M.D., EVP & CDO
 Anthony Mancini, EVP & COO
 Tahamtan Ahmadi, M.D., Ph.D., EVP & CMO, Head of Experimental Medicines

For more information/contact:
genmab.com / ir@genmab.com

¹Certain product candidates in development with partners, as noted; ²See local country prescribing information for precise indications; ³Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.; ⁴Products developed and marketed by others incorporating Genmab technology and innovation